Biotech drug developer Sagimet Biosciences is taking another shot at going public, according to a filing with the SEC late Friday.

Topics:  sagimet biosciences   sec   public   
BING NEWS:
  • Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from TD Cowen
    TD Cowen analyst Ritu Baral maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) today. The company’s shares ...
    11/21/2024 - 4:12 am | View Link
  • HC Wainwright Reaffirms “Buy” Rating for Sagimet Biosciences (NASDAQ:SGMT)
    HC Wainwright reissued their buy rating on shares of Sagimet Biosciences (NASDAQ:SGMT – Free Report) in a research report report published on Friday morning,Benzinga reports. The firm currently has a ...
    11/18/2024 - 11:01 am | View Link
  • Promising Outlook for Sagimet Biosciences: Buy Rating Driven by Denifanstat’s Clinical Success and Phase 3 MASH Program Initiation
    Analyst Ed Arce from H.C. Wainwright maintained a Buy rating on Sagimet Biosciences, Inc. Class A (SGMT – Research Report) and keeping ...
    11/15/2024 - 7:57 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News